Neoadjuvant therapy with vemurafenib in Horner's syndrome as a very rare first diagnosis of a malignant melanoma of unknown primary

J Dtsch Dermatol Ges. 2020 Jan;18(1):47-49. doi: 10.1111/ddg.13983. Epub 2019 Nov 19.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Female
  • Horner Syndrome / drug therapy*
  • Horner Syndrome / etiology
  • Humans
  • Magnetic Resonance Imaging
  • Melanoma / complications
  • Melanoma / secondary*
  • Middle Aged
  • Neoadjuvant Therapy*
  • Neoplasms, Unknown Primary / diagnostic imaging*
  • Pancoast Syndrome / diagnostic imaging
  • Pancoast Syndrome / drug therapy
  • Pancoast Syndrome / secondary*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Tomography, X-Ray Computed
  • Vemurafenib / therapeutic use*

Substances

  • Protein Kinase Inhibitors
  • Vemurafenib
  • Proto-Oncogene Proteins B-raf